PharmAust's phase II monepantel trials a success
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, has released promising data in relation to its monepantel canine trial.
Management provided an interim trial update for its veterinary Phase II clinical trial investigating the anti-cancer effects of monepantel tablets in dogs with treatment naïve B cell lymphoma.
In what management conservatively termed a ‘’successful outcome’’, a total of six of seven eligible and enrolled pet canine patients have completed assessment following “at home” treatment by their owners.
One dog failed to medicate in accordance with the study protocol and was removed from trial assessment early on.
This dog, however, continued receiving monepantel tablets and has now reached over 120 days of treatment with prednisolone added to the treatment regimen by the veterinary surgeon.
50% reduction in tumour burden with majority stabilised
Following 14 days of monepantel tablet treatment, the veterinarians reported that one dog achieved a partial response with a greater than 60% reduction in total tumour burden and with one lymph node tumour regressing completely.
Four dogs achieved stable disease and progressive disease was seen in one dog.
This outcome provides a meaningful trend, comparing favourably with the treatment used in the original “liquid” monepantel formula reported on 3 December 2017, where six of seven dogs achieved stable disease and progressive disease was seen in one dog.
After 14 days treatment, one dog with progressive disease and one with a partial response, but elevated liver enzymes, discontinued monepantel tablet treatment.
All four remaining dogs completed the 28-day treatment schedule, with all achieving stable measured lymph nodes.
A new lesion, however, became apparent in two of these dogs and some elevated liver enzyme values not resulting in clinical illness were also noted.
Plasma MPL levels were recorded for all dogs and reached levels up to 50 times higher than those recorded in the human trial undertaken at the Royal Adelaide Hospital in 2014/2015.
Some variability was observed in plasma levels and, unexpectedly, at the lower blood levels of MPL there were better outcomes.
This observation may be consistent with the mechanism of action of mTOR inhibitors and lends itself to reducing and optimising the future dosing of monepantel tablets.
Paves the way for phase III trials
Commenting on these outcomes, University of Melbourne and U-Vet Werribee’s Dr Claire Cannon, the principal investigator overseeing the trial, said, “Monepantel appears to be showing anti-cancer activity in dogs with lymphoma and I believe that controlled Phase III trials are now warranted to investigate the efficacy and safety of lower dose monepantel.
‘’The Phase II trial results suggest that monepantel, perhaps in combination with standard of care lymphoma therapy, may represent a future prospect for treatment of dogs with this disease.”
Based on these findings, the Phase II trial is now on hold while an Interim Report is finalised for Elanco US Inc, highlighting both the efficacy parameters as well as the induction of inappetence and elevated liver enzymes at very high dosage levels of MPL.
In discussing the prospects of improved outcomes in phase III trials, PharmAust’s Chief Scientific Officer Dr Richard Mollard said, “Having the monepantel tablets achieve a 60% reduction in tumour burden in one dog, with one lymph node returning to normal, is a terrific and unexpected outcome.
‘’The correlation of lower MPL blood levels with superior outcomes is also a very positive trend, providing flexibility for better outcomes in a future Phase III trial.”
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.